In vivo stabilization of nuclear retinoid X receptor α in the presence of peroxisome proliferator-activated receptor α  by Tanaka, Naoki et al.
In vivo stabilization of nuclear retinoid X receptor K in the presence of
peroxisome proliferator-activated receptor K
Naoki Tanakaa;b, Kazuhiko Horab, Hideki Makishimab, Yuji Kamijoa;b, Kendo Kiyosawab,
Frank J. Gonzalezc, Toshifumi Aoyamaa;
aDepartment of Aging Biochemistry, Research Center on Aging and Adaptation, Shinshu University School of Medicine, 3-1-1 Asahi,
Matsumoto 390-8621, Japan
bSecond Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan
cLaboratory of Metabolism, National Cancer Institute, Bethesda, MD 20892, USA
Received 27 January 2003; revised 5 April 2003; accepted 7 April 2003
First published online 1 May 2003
Edited by Giovanni Cesareni
Abstract Retinoid X receptor K (RXRK) can reveal diverse
functions through forming a heterodimer with peroxisome pro-
liferator-activated receptor K (PPARK). However, the mecha-
nism of regulation of the cellular RXRK level is unclear. Thus,
quantitative change of RXRK was investigated in mouse liver.
Nuclear RXRK level was constitutively lower in PPARK-null
mice than in wild-type mice. The level was also increased by
clo¢brate treatment in wild-type mice without a concomitant
increase of RXRK mRNA, but not in PPARK-null mice. Pulse
chase experiments demonstrated that the presence of PPARK
and its activation by ligands signi¢cantly a¡ected the stability of
nuclear RXRK. These ¢ndings suggest a novel regulatory mech-
anism of nuclear RXRK in vivo.
& 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
Key words: Retinoid X receptor K ;
Peroxisome proliferator-activated receptor K ; Heterodimer;
Stabilization
1. Introduction
The peroxisome proliferator-activated receptor (PPAR)
family is a member of the steroid/thyroid hormone receptor
superfamily, and consists of distinct genes designated PPARK,
L or N, and Q [1,2]. PPARK is highly expressed in hepatocytes,
epithelial cells of the digestive tract and renal proximal tubu-
lar cells of both rodents and humans [3,4], and plays diverse
roles including the maintenance of lipid and glucose homeo-
stasis [5,6], regulation of cell proliferation [7,8] and modula-
tion of in£ammatory responses [9,10].
PPAR forms a heterodimer with retinoid X receptor (RXR)
to generate a complex that binds to the peroxisome prolifer-
ator response element in the promoter region of target gene
and activates its transcription [1,2,11^13]. The extent of the
transcriptional activation is known to be in£uenced by various
factors, including its ligands, coactivators, transcription fac-
tors and other nuclear receptors [1,2].
Of the three isoforms of RXR, RXRK is the most abundant
in the liver [14]. Recently, Wan et al. established a mouse line
lacking RXRK speci¢cally in the hepatocytes, demonstrating
that RXRK plays an important role in the action of hepatic
PPARK [15,16]. Moreover, the mRNA level of hepatic PPARK
is constitutively upregulated in these mice [15], suggesting that
RXRK can a¡ect the quantity of its heterodimeric partner
PPARK. Since heterodimer formation between PPAR and
RXRK might be important for quantitative regulation of these
nuclear receptors, we examined it in detail. PPARK-null mice
were used, because they have relatively normal phenotypes
[17] and are thus suitable for serial in vivo analyses [18,19].
2. Materials and methods
2.1. Animals and clo¢brate treatment
PPARK-null mice on an Sv/129 genetic background were generated
as described elsewhere [17]. Twelve-week-old wild-type Sv/129 male
mice (n=12) and age- and sex-matched PPARK-null mice (n=12)
were used. The mice were fed either a control diet or one containing
0.75% (w/w) clo¢brate (Wako Chemicals, Osaka, Japan) for 2 weeks.
After treatment, the mice were killed and their livers excised. The
feeding period and clo¢brate content in the diet respectively were
changed in the time course and dose^response experiment (see ¢gure
legends).
2.2. Immunoblot analysis
Nuclear extracts prepared from the mouse liver homogenates were
used for the immunoblot analysis. Protein of the hepatocyte nuclear
extracts (100 Wg) was subjected to 10% sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) and transferred to nitro-
cellulose membranes. The membranes were incubated ¢rst with the
primary antibody, and then with alkaline phosphatase-conjugated
anti-rabbit or anti-goat IgG. The primary antibodies used (RXRK,
D-20; PPARK, H-98; PPARL, H-74; PPARQ, H-100) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). RXRK
(D-20) reacts speci¢cally with RXRK of mouse and human origin
and is non-cross-reactive with RXRL and RXRQ. PPARK (H-98),
PPARL (H-74) and PPARQ (H-100) react speci¢cally with PPARK,
PPARL and PPARQ of mouse and human origin, respectively. In the
preliminary immunoblot experiments, the band positions of these four
proteins were con¢rmed. Brie£y, the band positions of nuclear RXRK
and PPARK were determined by co-electrophoresis with cDNA-ex-
pressed RXRK [20] and PPARK [21], respectively. The band positions
of nuclear PPARL and PPARQ were estimated by co-electrophoresis
with cDNA-expressed PPARK and double immunostaining, respec-
tively, because the molecular weight of PPARK (52 kDa) is closely
similar to that of PPARL or PPARQ [22].
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2.3. mRNA analysis
Northern blotting was used for mRNA analysis. Total liver RNA
was extracted with an RNeasy Mini Kit1 (Qiagen, Valencia, CA,
USA), electrophoresed on 1.1 M formaldehyde-containing 1% agarose
gels and transferred to nylon membranes. The membranes were incu-
bated with 32P-labelled cDNA probes and analyzed on a Fuji system
analyzer (Fuji Photo Film, Tokyo, Japan). The cDNAs for PPARs,
RXRK and cellular retinol-binding protein II (CRBPII), used as
probes, were generated by reverse transcription-polymerase chain re-
action. Total RNA extracted from the liver of the clo¢brate-treated
mice was used as a template. The primer pairs were designed on the
basis of the following published cDNA sequences: 5P-TGAC-
GTTTGTGGCTGGTCAA-3P and 5P-CAGAGATTTGAGGTCTG-
CAG-3P for PPARK [21]; 5P-AGAACACACGCTTCCTTCCA-3P
and 5P-ATTGAGGAAGAGGCTGCTGA-3P for PPARL [22]; 5P-AC-
CAACTTCGGAATCAGCTC-3P and 5P-GGGAAGGACTTTATG-
TATGA-3P for PPARQ [23] ; 5P-GTTGGGCGACTTTTGCAACA-3P
and 5P-TTTGCGTACTGTCCTCTTGA-3P for RXRK [20], and 5P-
GGTGGAGTTTGACGAACACAC-3P and 5P-TTTGAACACTT-
GTCGGCACAC-3P for CRBPII [24]. The ampli¢ed cDNA fragments
for PPARK, L, Q, RXRK, and CRBPII were 705, 730, 644, 589, and
192 bp in size, respectively. The authenticity of these fragments was
con¢rmed by bidirectional sequencing using a BigDye Terminator
Cycle Sequencing FS Ready Reaction Kit0 and an ABI Prism 310
genetic analyzer (both from Applied Biosystems, Foster City, CA,
USA). The origin of mouse cDNAs for peroxisomal thiolase (PT)
and L-actin is described elsewhere [5,17].
2.4. Hepatocyte isolation, culture and clo¢brate treatment
Parenchymal hepatocytes were isolated from the control or clo¢-
brate-treated mice with the modi¢ed in situ perfusion method [25].
After perfusion with 0.05% collagenase solution (Wako Chemicals),
the isolated hepatocytes were washed three times by means of di¡er-
ential centrifugation and the dead cells were removed by density gra-
dient centrifugation on Percoll (Amersham Pharmacia Biotech, Buck-
inghamshire, UK). The live parenchymal hepatocytes were then
washed and suspended in CL15 medium containing 8.3% fetal bovine
serum. The viability of the isolated hepatocytes was s 90% as deter-
mined by the trypan blue test. Primary monolayer cultures of hepa-
tocytes and monolayer harvesting were performed as described pre-
viously [26]. Clo¢brate was dissolved in dimethyl sulfoxide (DMSO)
and added at each change of the medium for a ¢nal clo¢brate con-
centration of 0.3 mM to maintain the e¡ects. Control cells were cul-
tured in medium containing the same ¢nal concentration of DMSO
(0.15%, v/v). The hepatocytes were cultured for 5 days.
2.5. Pulse label and pulse chase experiment
Cultured hepatocytes were washed with methionine-free medium
containing 5% (v/v) dialyzed fetal bovine serum and then incubated
for 2 h in the same medium at 37‡C. The medium was replaced with
the same medium containing 300 WCi/ml of [35S]methionine (Amer-
sham Pharmacia Biotech). After a 2-h incubation, the labelling me-
dium was changed to the standard medium, and the preparation was
chased for 3, 6, or 12 h. The labelled cells were then washed twice with
phosphate-bu¡ered saline, homogenized and centrifuged in prepara-
tion for nuclear fraction. The radioactivity in the homogenates was
measured and showed values almost identical to those of the pulse-
labelled preparations, suggesting that the [35S]methionine uptake ca-
pacity is similar for these hepatocyte groups. The nuclear fraction was
lysed in RIPA bu¡er (10 mM Tris^HCl, pH 7.5, 0.2% sodium deoxy-
cholate, 0.2% Nonidet P-40, 0.1% SDS, 0.25 mM phenylmethylsul-
fonyl £uoride, 10 mg/ml aprotinin). The lysate, in a volume of 350 Wl,
was reacted for 3 h at 4‡C with puri¢ed anti-RXRK antibody. The
immune complexes were precipitated with Staphylococcus aureus pro-
tein A bound to agarose beads. After the precipitates had been
washed three times in RIPA bu¡er, the labelled proteins were resolved
by means of 10% SDS^PAGE and visualized by autoradiography with
the aid of a Fuji system analyzer (Fuji Photo Film). The nuclear
fractions of the pulse-labelled preparations were also used for immu-
noblot analysis of RXRK.
2.6. Hepatocyte culture and 9-cis-retinoic acid treatment
Parenchymal hepatocytes were isolated from wild-type or PPARK-
null mice and cultured. 9-cis-Retinoic acid (ICN Biomedicals, Costa
Mesa, CA, USA) was dissolved in DMSO and added to the medium
to make a ¢nal concentration of 1 WM. Control cells were cultured in
medium containing the same ¢nal concentration of DMSO (0.1%,
v/v). The hepatocytes were incubated for 24 h, harvested and sub-
jected to mRNA analysis.
2.7. Statistical analysis
Results are expressed as the meansSS.D. Group means were com-
pared using analysis of variance followed by Student’s t-test.
3. Results
3.1. Analysis of RXRK and PPARs in mouse livers
To examine the expression of hepatic RXRK and PPARs,
immunoblot analysis using nuclear fractions was performed.
The nuclear RXRK level in the wild-type mice was constitu-
tively higher than that in the PPARK-null mice (Fig. 1A,B).
The level was signi¢cantly increased by clo¢brate treatment,
which is known to induce hepatic PPARK and stimulate the
transcription of its target genes such as fatty acid-metaboliz-
ing enzymes [5,17,27]. The PPARK levels in the nuclear frac-
tions from the wild-type mouse livers increased by clo¢brate
Fig. 1. Immunoblot analysis of RXRK and PPARs. A: Each lane
was loaded with 100 Wg of protein of nuclear extracts prepared
from the individual mouse livers. After electrophoresis, the blots
were stained with antibodies against RXRK, PPARK, L and Q. The
arrowheads represent the positions of the proteins. Genotype and
diet are indicated. PPARKþ=þ, wild-type Sv/129 mice; PPARK3=3,
PPARK-null mice. B: The band intensity of nuclear RXRK and
PPARs was quanti¢ed densitometrically and expressed as the fold
change relative to the control wild-type mice. Values are expressed
as the meansSS.D. (n=6). *P6 0.01 compared with the control
wild-type mice. PPARKþ=þ (open bar), wild-type Sv/129 mice;
PPARK3=3 (closed bar), PPARK-null mice.
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treatment, as expected. The levels of PPARL and PPARQ
remained relatively constant in all cases (Fig. 1A,B). These
results demonstrate that the protein level of RXRK is a¡ected
by cellular level of PPARK and its ligand.
3.2. mRNA analysis of RXRK and PPARK
To determine whether the correlative changes in RXRK and
PPARK at the protein level correspond to those at the tran-
scriptional level, Northern blot analysis was performed. Inter-
estingly, the levels of RXRK mRNA remained virtually con-
stant in all cases. In contrast, the level of PPARK mRNA in
the wild-type mice was increased by clo¢brate treatment, as
expected (Fig. 2). The levels of PPARL and PPARQ mRNA
remained unchanged in all the samples (data not shown).
These results suggest that the changes in RXRK at the protein
level are due to post-transcriptional events.
3.3. Correlative changes in nuclear RXRK and PPARK
To further characterize the correlative changes in nuclear
RXRK and PPARK, time course and dose^response experi-
ments concerning clo¢brate treatment were performed. The
levels of nuclear RXRK and PPARK in the wild-type mice
increased rapidly until 4 and 2 days after starting clo¢brate
treatment, respectively, and these levels were nearly constant
until 14 days. The level of nuclear RXRK in the PPARK-null
mice was practically unchanged. The changes of RXRK level
in the wild-type mice were similar to those of PPARK level
(Fig. 3A). In the dose^response experiment, the levels of nu-
clear RXRK and PPARK in the wild-type mice were increased
to 0.1% (w/w) clo¢brate concentration, and these levels were
practically constant at the higher concentrations. The dose^
response changes of RXRK in the wild-type mice were similar
to those of PPARK (Fig. 3B). These results con¢rm the syn-
chronous changes in nuclear RXRK and PPARK.
3.4. Stabilization of nuclear RXRK by PPARK
To investigate the stability of nuclear RXRK, pulse chase
experiments were performed using hepatocytes isolated from
the mouse livers. There was little di¡erence in the band inten-
sity of pulse labelling (P in Fig. 4A) among the four isolated
hepatocyte groups, demonstrating that transfer of RXRK into
the nucleus does not di¡er between the hepatocyte groups.
The half-life of nuclear RXRK in the hepatocytes from the
control wild-type mice was approximately 7.5 h. This in-
creased to approximately 12 h by clo¢brate treatment (Fig.
4A,B). On the other hand, the half-life in the hepatocytes
from the control PPARK-null mice was approximately 4.5 h,
and was not changed by clo¢brate treatment (Fig. 4A,B). The
levels of RXRK in the nuclear extracts used in the pulse chase
experiments (Fig. 4C) showed a similar tendency to those in
vivo (Fig. 1A). To summarize, the stability of nuclear RXRK
in the control wild-type mice was higher than that in the
control PPARK-null mice and considerably increased by clo-
¢brate treatment, which was probably re£ected in the levels of
RXRK in the hepatocyte samples. The stability and the resul-
tant protein level of nuclear RXRK seem to be regulated by
nuclear PPARK, since RXRK can heterodimerize with PPARK
[1,2,11,13]. Indeed, the degree of its stability roughly corre-
Fig. 2. mRNA analysis of RXRK and PPARK. Total RNA ex-
tracted from three individual mouse livers was electrophoresed
(10 Wg), blotted and hybridized with radiolabelled cDNA probes for
RXRK, PPARK and L-actin, respectively. The abbreviations used
are shown in the legend of Fig. 1
Fig. 3. Changes in nuclear RXRK and PPARK. A: Time course ex-
periment concerning clo¢brate treatment. The wild-type and
PPARK-null mice were fed with a control diet or one containing
0.75% (w/w) clo¢brate for 0.5, 1, 2, 4, 7, or 14 days. Protein of nu-
clear extracts (100 Wg) prepared from the individual mouse livers
was subjected to immunoblot analysis. The band intensity of nuclear
RXRK and PPARK was quanti¢ed densitometrically, expressed as
the fold change relative to the control wild-type mice and plotted.
Values are expressed as the meansSS.D. (n=4). b, RXRK level in
the wild-type mice; a, PPARK level in the wild-type mice; F,
RXRK level in the PPARK-null mice. B: Dose^response experiment
concerning clo¢brate treatment. The wild-type and PPARK-null
mice were fed with a control diet or one containing 0.05, 0.10, 0.25,
or 0.75% (w/w) clo¢brate for 2 weeks. Nuclear RXRK and PPARK
levels were plotted as described in A. Values are expressed as the
meansSS.D. (n=4). The symbols are as described in A.
Fig. 4. Pulse label and pulse chase experiment using isolated hepato-
cytes. A: Labelled RXRK bands on X-ray ¢lm. Pulse chase and
pulse label experiment was performed as described in Section 2. The
arrowheads indicate the position of RXRK. P, pulse label; 3, 6, 12
h, pulse chase for 3, 6, 12 h; PPARKþ=þ, wild-type Sv/129 mice;
PPARK3=3, PPARK-null mice; +CF, clo¢brate treatment. B: Inten-
sity plot of RXRK band in ¢ve individual experiments. The band
intensity of labelled RXRK was quanti¢ed densitometrically, ex-
pressed as a percentage of pulse-labelled band intensity and plotted.
Values are expressed as the meansSS.D. *P6 0.01 compared with
isolated hepatocyte group from the control wild-type mice; a, con-
trol wild-type mice; b, clo¢brate-treated wild-type mice; E, control
PPARK-null mice; F, clo¢brate-treated PPARK-null mice. C: Im-
munoblot analysis of isolated hepatocyte nuclear fractions. The
same samples as those used in A were electrophoresed and blotted.
The blot was stained with the antibody against RXRK. The arrow-
head indicates the position of RXRK.
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lates with the protein level of nuclear PPARK (Figs. 1, 3 and
4).
3.5. In£uence of RXRK stabilization on its function
The CRBPII gene possesses a retinoid X response element
in the promoter region and its transcription is enhanced by
the binding of RXRK homodimer [28]. The transcription of
the PT gene is also activated by the PPARK/RXRK hetero-
dimer, similar to other PPARK target genes such as peroxi-
somal acyl-CoA oxidase gene and mitochondrial medium
chain acyl-CoA dehydrogenase gene [2,5]. When analyzing
the mRNA levels of CRBPII and PT, the former level in-
creased and the latter increased markedly by clo¢brate treat-
ment (Fig. 5A). Additionally, the increase of functional acti-
vation of RXRK was further examined in the experiment
using primary hepatocytes and 9-cis-retinoic acid, a RXRK-
speci¢c agonist. The mRNA level of CRBPII signi¢cantly in-
creased in the wild-type hepatocytes treated with 9-cis-retinoic
acid and increased to some degree in the treated PPARK-null
hepatocytes (Fig. 5B). These results demonstrate that the nu-
clear RXRK stabilization and the resultant protein increase
can enhance its activity in the transcription of target genes.
4. Discussion
Nuclear RXRK was increased in clo¢brate-treated wild-type
mice through its stabilization. A similar stabilization and in-
crease of nuclear RXRK was found in the control wild-type
mice, in comparison with the control PPARK-null mice. These
¢ndings indicate the presence of a novel mechanism for the
regulation of the nuclear RXRK level through the interaction
with PPARK. Since PPARK/RXRK heterodimer formation is
essential for its functional activation and the resultant tran-
scriptional activation or suppression of its target genes [1,2,
11,13], these ¢ndings may well be important for maintaining a
balanced simultaneous increase of RXRK and PPARK in
order to enhance their functional association. Moreover, the
signi¢cant RXRK stabilization accompanied an enhancement
of target gene expression regulated by the RXRK homodimer.
This suggests that the activation of PPARK may a¡ect the
functional activation of various RXRK-associated metabolic
pathways.
Hirotani et al. showed that, as a result of coexpression of
RXRK in HeLa cells, ectopically expressed PPARK was sta-
bilized through heterodimerization with RXRK [29]. In the
present study, the levels of nuclear RXRK and PPAR were
examined in mouse livers, leading to a more accurate re£ec-
tion of in vivo phenomena.
In the absence of PPARK, RXRK forms a homodimer or
various heterodimer species with other nuclear receptors such
as retinoic acid receptor, farnesoid X receptor and the other
PPAR isoforms [1,13,30,31]. Since RXRK is less stable and its
nuclear level is lower in PPARK-null mice, it is supposed that
the absence of PPARK in£uences many signalling pathways
regulated by the RXRK homodimer and several other hetero-
dimers in the liver [28,31]. In human livers, the level of PPARK
is much lower than that in rodent livers [32]. Therefore,
PPARK-null mice may be a useful model animal to estimate
the role of RXRK-mediated signalling pathways in humans.
The precise mechanism of stabilization of RXRK by PPARK
ligand and by exposure to PPARK is not yet understood.
Perhaps, binding of RXRK to its partner protects it against
proteolytic degradation. In the absence of PPARK, RXRK
would be expected to bind many other heterodimeric partners
such as the thyroid hormone receptor, vitamin D receptor,
liver X receptor, or others [1,13,33,34]. Although the precise
cellular levels of these nuclear receptors in the liver are not
known in the mouse, binding of RXRK to these nuclear re-
ceptors seems to be unable to compensate the role of PPARK.
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